methods for treating triple-negative breast cancer (TNBC), which is known for poor prognosis and high rate of mortality. Two types of novel dual-targeting TNBC liposomes (Fru-RGD-Lip and Fru+RGD-Lip) that actively recognize both fructose transporter GLUT5 and integrin αvβ3 were designed and prepared in this work. Firstly, a Y-shaped Fru-RGD-chol ligand, where a fructose and peptide Arg-Gly-Asp (RGD) were
目前,
化学疗法和放射疗法仍然是治疗三阴性乳腺癌(T
NBC)的主流方法,该方法以预后不良和高死亡率着称。在这项工作中,设计并制备了两种可以主动识别
果糖转运蛋白GLUT5和整联蛋白αvβ3的新型双靶向T
NBC脂质体(Fru-RGD-Lip和Fru + RGD-Lip)。首先,设计并合成了Y型Fru-RGD-chol
配体,其中
果糖和肽Arg-Gly-Asp(RGD)共价附于
胆固醇。然后,通过将Fru-RGD-chol插入脂质体中构建Fru-RGD-Lip,而通过将Fru-chol和RGD-chol(摩尔比为1:1)插入脂质体中获得Fru + RGD-Lip。 。粒度,ζ电势,
紫杉醇脂质体的包封效率和血清稳定性进行了表征。结果表明,载有
紫杉醇的Fru-RGD-Lip对GLUT5和过度表达的
MDA-MB-231和4T1细胞的αvβ3具有最强的生长抑制作用。Fru-RGD-Lip在
MDA-MB-231